News & Videos - ALLIGATOR BIOSCIENCE AB [CBOE]

Alligator Bioscience Announces Completion of 600 mg Dose Cohort for ATOR-1017, Dose-escalation and Enrollment for 900 mg dose Cohort Commences PR Newswire LUND, Sweden, April 1, 2022 LUND, Sweden , April 1, 2022 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the completion of the patient enrollment for the 600 mg dose cohort from Alligator's Phase I, first-in-human clinical trial with the 4-1BB (CD137) targeting drug candidate, ATOR-1017, which is being developed...

Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update: Successful Completion of Phase Ib, Phase II enrolling at 900 µg/kg PR Newswire LUND, Sweden, March 23, 2022 LUND, Sweden , March 23, 2022 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an update on the ongoing OPTIMIZE-1 clinical Phase Ib/II trial in first-line metastatic pancreatic cancer with the company's lead asset, mitazalimab. Safety evaluation of the second dose-escalation cohort (900...

Alligator Bioscience AB: Year End report January-December 2021 PR Newswire STOCKHOLM, Feb. 11, 2022 STOCKHOLM , Feb. 11, 2022 /PRNewswire/ -- OPTIMIZE-1 Phase II - On Track and Moving Forward "During the fourth quarter 2021, Alligator reached several key milestones in our pre-clinical, clinical, and partnered programs. Our priorities continue to be shaped by the rising need for cancer drug therapies that are safer and more effective." Søren Bregenholt CEO Alligator Bioscience AB (publ)...

Alligator Bioscience AB: Year End report January-December 2021 PR Newswire STOCKHOLM, Feb. 11, 2022 STOCKHOLM , Feb. 11, 2022 /PRNewswire/ -- OPTIMIZE-1 Phase II - On Track and Moving Forward "During the fourth quarter 2021, Alligator reached several key milestones in our pre-clinical, clinical, and partnered programs. Our priorities continue to be shaped by the rising need for cancer drug therapies that are safer and more effective." Søren Bregenholt CEO Alligator Bioscience AB (publ)...

Alligator Bioscience Appoints Sumeet Ambarkhane MD as Chief Medical Officer PR Newswire LUND, Sweden, Feb. 1, 2022 LUND, Sweden , Feb. 1, 2022 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces the appointment of Sumeet Ambarkhane, MD, as its Chief Medical Officer. In this role, Sumeet will provide medical leadership and direction in the development of Alligator's best-in-class preclinical and clinical pipeline,...

Alligator Bioscience Announces Commencement of a Sponsored Research Agreement with the University of Pennsylvania Led by Dr. Gregory Beatty PR Newswire LUND, Sweden, Jan. 19, 2022 LUND, Sweden , Jan. 19, 2022 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the initiation a sponsored research collaboration to study biomarker data from Alligator's OPTIMIZE-1 study with the University of Pennsylvania's (UPENN) Pancreatic Cancer Research Center. Gregory Beatty , MD,...

Alligator Bioscience Announces Commencement of a Sponsored Research Agreement with the University of Pennsylvania Led by Dr. Gregory Beatty PR Newswire LUND, Sweden, Jan. 19, 2022 LUND, Sweden , Jan. 19, 2022 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the initiation a sponsored research collaboration to study biomarker data from Alligator's OPTIMIZE-1 study with the University of Pennsylvania's (UPENN) Pancreatic Cancer Research Center. Gregory Beatty , MD,...

Alligator Bioscience Announces OPTIMIZE-1 Trial Update: Cohort Fully Dosed with No Adverse Effects Reported PR Newswire LUND, Sweden, Jan. 18, 2022 LUND, Sweden , Jan. 18, 2022 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an update on the on-going OPTIMIZE-1 clinical Phase Ib/II trial with the company's lead asset, mitazalimab. All patients in the 450 µg/kg cohort have been dosed and there have been no adverse effects related to study medication has been...

Alligator Bioscience Announces Trial Update and Early Readout for ATOR-1017 Confirming Biomarker, Safety & Tolerability Data PR Newswire LUND, Sweden, Dec. 16, 2021 LUND, Sweden , Dec. 16, 2021 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an update on the on-going clinical Phase I trial with the 4-1BB (CD137) drug candidate ATOR-1017, which is developed as a tumor-directed therapy for metastatic cancer. The early readout data corroborates previous data on...

Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal Nature Communication PR Newswire LUND, Sweden and SEATTLE, Dec. 15, 2021 LUND, Sweden and SEATTLE , Dec. 15, 2021 /PRNewswire/ -- Alligator Bioscience AB (" Alligator ") and Aptevo Therapeutics ("Aptevo") (NASDAQ: APVO) today announced publication of an article in the December 15, 2021, issue of the peer-reviewed journal, Nature Communications on the mechanism of action of CD137 (4-1BB) targeting...

Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal Nature Communication PR Newswire LUND, Sweden and SEATTLE, Dec. 15, 2021 LUND, Sweden and SEATTLE , Dec. 15, 2021 /PRNewswire/ -- Alligator Bioscience AB (" Alligator ") and Aptevo Therapeutics ("Aptevo") (NASDAQ: APVO) today announced publication of an article in the December 15, 2021, issue of the peer-reviewed journal, Nature Communications on the mechanism of action of CD137 (4-1BB) targeting...

Alligator Bioscience Announces Commencement of Investigator Initiated Phase I Clinical Trial at Erasmus University Rotterdam First Patient Dosed in Study Evaluating Mitazalimab in Combination with Cancer Vaccine for Patients with Pancreatic Cancer PR Newswire LUND, Sweden, Nov. 8, 2021 LUND, Sweden , Nov. 8, 2021 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the initiation of a proof-of-concept Phase Ib clinical trial to assess the safety and efficacy of...

Bulletin from the extraordinary general meeting in Alligator Bioscience AB PR Newswire LUND, Sweden, Nov. 8, 2021 LUND, Sweden , Nov. 8, 2021 /PRNewswire/ -- Today, on 8 November 2021 , an extraordinary general meeting was held in Alligator Bioscience AB. A summary of the adopted resolutions follows below. In light of the ongoing Covid-19 pandemic and in order to reduce the risk of infection spreading, the meeting was held only by advance voting (postal vote) in accordance with temporary...

Bulletin from the extraordinary general meeting in Alligator Bioscience AB PR Newswire LUND, Sweden, Nov. 8, 2021 LUND, Sweden , Nov. 8, 2021 /PRNewswire/ -- Today, on 8 November 2021 , an extraordinary general meeting was held in Alligator Bioscience AB. A summary of the adopted resolutions follows below. In light of the ongoing Covid-19 pandemic and in order to reduce the risk of infection spreading, the meeting was held only by advance voting (postal vote) in accordance with temporary...

Alligator Bioscience AB: Interim report January-September 2021 PR Newswire STOCKHOLM, Oct. 21, 2021 STOCKHOLM , Oct. 21, 2021 /PRNewswire/ -- First Patient Dosed in Optimize-1 Phase II "We continued to make great strides in the third quarter of 2021. The first patient was dosed in OPTIMIZE-1, our clinical Phase II study, that will assess the effect of mitazalimab in first line pancreatic cancer. We entered a collaboration with Finnish based Orion Corporation focusing on the discovery of novel...

Alligator Bioscience AB: Interim report January-September 2021 PR Newswire STOCKHOLM, Oct. 21, 2021 STOCKHOLM , Oct. 21, 2021 /PRNewswire/ -- First Patient Dosed in Optimize-1 Phase II "We continued to make great strides in the third quarter of 2021. The first patient was dosed in OPTIMIZE-1, our clinical Phase II study, that will assess the effect of mitazalimab in first line pancreatic cancer. We entered a collaboration with Finnish based Orion Corporation focusing on the discovery of novel...

Notice of extraordinary general meeting in Alligator Bioscience AB PR Newswire STOCKHOLM, Oct. 7, 2021 STOCKHOLM , Oct. 7, 2021 /PRNewswire/ -- The shareholders of Alligator Bioscience AB, Reg. No. 556597-8201 ("Alligator"), are invited to the extraordinary general meeting to be held on Monday 8 November 2021 . In light of the ongoing Covid-19 pandemic and in order to reduce the risk of infection spreading, the board of directors has decided that the meeting will be held only by advance voting...

Alligator is exploring financing alternatives to support phase II studies for Mitazalimab, phase II preparations for ATOR-1017 as well as the development of other pipeline PR Newswire LUND, Sweden, Sept. 2, 2021 LUND, Sweden , Sept. 2, 2021 /PRNewswire/ -- Alligator Bioscience AB (" Alligator " or the " Company ") today announces that the Company, in order to enable further progress, will begin evaluating potential financing alternatives, which may include issuance of equity. Alligator's board...

Positive Results from the Scandion Oncology and Alligator Bioscience Collaboration Further Supports Efficacy of Mitazalimab in Combination Therapy PR Newswire STOCKHOLM, Sept. 2, 2021 STOCKHOLM , Sept. 2, 2021 /PRNewswire/ -- Alligator Bioscience AB (Nasdaq Stockholm: ATORX) and Scandion Oncology A/S (Nasdaq Stockholm: SCOL), today announced the conclusion of their collaboration with a very positive outcome. The purpose of the collaboration was to explore the anti-tumor efficacy of the CD40...

Alligator Bioscience announces Immuno-oncology Research Collaboration and License Agreement with Orion Corporation PR Newswire STOCKHOLM, Aug. 18, 2021 STOCKHOLM , Aug. 18, 2021 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that the company has entered into a research collaboration and license agreement with Orion Corporation, a global pharmaceutical company based in Finland , to discover and develop together new bispecific antibody cancer therapeutics The...